Immuno-Oncology Startup Snatches $67m In Series A

NextCure, a newly formed immuno-oncology company being led by Michael Richman, the former CEO of AstraZeneca plc-acquired biotech Amplimmune, has raised $67m in a series A financing round.

NextCure, a newly formed immuno-oncology company being led by Michael Richman, the former CEO of AstraZeneca plc-acquired biotech Amplimmune, has raised $67m in a series A financing round.

Major investors in the financing included Canaan Partners, Lilly Asia Ventures, OrbiMed Advisors, Pfizer Inc., Sofinnova Ventures and Alexandria Venture...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category